MedPath

Can Symptom monitoring With Feedback to clinicians improve the lives of people on dialysis? (SWIFT) - Pilot study of acceptability and feasibility

Not Applicable
Conditions
End Stage Kidney Disease
Quality of Life
Renal and Urogenital - Kidney disease
Public Health - Health service research
Registration Number
ACTRN12618001976279
Lead Sponsor
HMRC Clinical Trials Centre - University of Sydney
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
183
Inclusion Criteria

Adults aged 18 years and older with ESKD receiving in-centre haemodialysis or haemodiafiltration.

Exclusion Criteria

Non - English speaking participants who would require additional translation services that are not existing as part of usual care
Patients likely to be transplanted or transitioned to PD or Home HD within the next 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall response rate of EQ-5D-5L & IPOS renal surveys calculated as the number of complete surveys over the total number of surveys given to patients[EQ-5D-5L surveys at baseline and 6 months and IPOS-Renal surveys at baseline, 3 and 6 months];Overall completeness of surveys, calculated as the proportion of core questions completed per survey (some questions from the IPOS Renal are optional and these will not be included in completeness calculations)[EQ-5D-5L surveys at baseline and 6 months and IPOS-Renal surveys at baseline, 3 and 6 months];Thematic analysis of transcripts from interviews with nurse unit managers and nephrologists and focus groups with patients to elicit the facilitators and barriers to implementation of electronic patient reported outcome measures (ePROMs)[Focus groups and interviews with patients and clinical staff after completion of the 6 month ePROMs data collection]
Secondary Outcome Measures
NameTimeMethod
Time taken to complete ePROMs data collection, measured using metrics built into Qualtrics[EQ-5D-5L surveys at baseline and 6 months and IPOS-Renal surveys at baseline, 3 and 6 months];Email activity metrics (measured via Mail Chimp) to examine the proportion of feedback emails that were opened[Baseline, 3 and 6 months for intervention arm (no measurement for control arm as no symptom score emails are sent)];Representativeness of patient population, by examining the cohort who participated in the trial compared to the eligible cohort (identified using ANZDATA)[Total number of participants at each site who were enrolled in the trial at the time of site commencement, compared to those eligible for participation at the time of site enrolment.]
© Copyright 2025. All Rights Reserved by MedPath